FibroBiologics (FBLG) Expected to Release Earnings on Thursday

FibroBiologics (NASDAQ:FBLG) is expected to be issuing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($0.93) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

FibroBiologics (NASDAQ:FBLG) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.33) EPS for the quarter, hitting the consensus estimate of ($1.33). On average, analysts expect FibroBiologics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

FibroBiologics Stock Performance

Shares of FBLG opened at $0.65 on Wednesday. The firm has a market cap of $3.95 million, a P/E ratio of -0.09 and a beta of 1.14. FibroBiologics has a twelve month low of $0.62 and a twelve month high of $13.16. The firm’s 50 day moving average price is $0.89 and its two-hundred day moving average price is $3.11.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on FBLG shares. Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday. Maxim Group lowered shares of FibroBiologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. HC Wainwright restated a “buy” rating and set a $8.00 target price (up from $4.00) on shares of FibroBiologics in a report on Thursday, April 16th. Finally, Wall Street Zen raised shares of FibroBiologics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, FibroBiologics has a consensus rating of “Hold” and an average target price of $74.00.

Institutional Investors Weigh In On FibroBiologics

Large investors have recently made changes to their positions in the stock. AQR Capital Management LLC acquired a new position in FibroBiologics during the first quarter worth $29,000. XTX Topco Ltd grew its position in shares of FibroBiologics by 160.0% in the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after acquiring an additional 28,276 shares during the period. Jane Street Group LLC acquired a new position in shares of FibroBiologics during the 4th quarter worth about $34,000. Marshall Wace LLP bought a new stake in shares of FibroBiologics in the 2nd quarter valued at about $49,000. Finally, Renaissance Technologies LLC lifted its stake in FibroBiologics by 287.3% in the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after purchasing an additional 171,800 shares during the last quarter.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.